Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Abatacept

Nature Reviews Drug Discovery volume 5, pages 185–186 (2006)Cite this article

Abstract

In December 2005, abatacept (Orencia; Bristol-Myers Squibb), a fusion protein that selectively modulates a costimulatory signal necessary for T-cell activation, was approved by the US FDA for the treatment of patients with rheumatoid arthritis who have had an inadequate response to other drugs. It is the first selective costimulation modulator to be approved.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Activity of abatacept.

References

  1. Smolen, J. S. & Steiner, G. Therapeutic strategies for rheumatoid arthritis. Nature Rev. Drug Discov. 2, 473–488 (2003).

    Article  CAS  Google Scholar 

  2. Reiser H. & Stadecker, M. J. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N. Engl. J. Med. 335, 1369–1377 (1996).

    Article  CAS  Google Scholar 

  3. Linsley, P. S. et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174, 561–569 (1991).

    Article  CAS  Google Scholar 

  4. Linsley, P. S. et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 257, 792–795 (1992).

    Article  CAS  Google Scholar 

  5. FDA labelling information [online], <http://www.fda.gov/cder/foi/label/2005/125118lbl.pdf> (2005).

  6. Webb, L. M., Walmsley, M. J. & Feldmann, M. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur. J. Immunol. 26, 2320–2328 (1996).

    Article  CAS  Google Scholar 

  7. Moreland, L. W. et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 46, 1470–1479 (2002).

    Article  CAS  Google Scholar 

  8. Kremer J. M. et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349, 1907–1915 (2003).

    Article  CAS  Google Scholar 

  9. Genovese, M. C. et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N. Engl. J. Med. 353, 1114–1123 (2005).

    Article  CAS  Google Scholar 

  10. Lipsky, P. E. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 343, 1594–1602 (2000).

    Article  CAS  Google Scholar 

  11. Klareskog, L. et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 363, 675–681 (2004).

    Article  CAS  Google Scholar 

  12. Breedveld, F. C. et al. The PREMIER Study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54, 26–37 (2006).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. the Department of Medicine, University of Alabama, 1717 6th Ave South, Birmingham, 35294-7201, Alabama, USA

    Larry Moreland

  2. IMS Health, 7 Harewood Avenue, London, NW1 6JB, UK

    Guy Bate

  3. Nature Reviews Drug Discovery, UK

    Peter Kirkpatrick

Authors
  1. Larry Moreland
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guy Bate
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moreland, L., Bate, G. & Kirkpatrick, P. Abatacept. Nat Rev Drug Discov 5, 185–186 (2006). https://doi.org/10.1038/nrd1989

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1989

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing